The recent debate over flexible working has been reduced to a simplistic argument about whether people should be in the office three days a week or four. This narrow focus overlooks a more significant ...
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2–Activating Mutations: Results From the National Cancer Institute–Molecular Analysis for Therapy Choice ...
Riluzole is a glutamate-modulating agent with neuroprotective properties approved for use in amyotrophic lateral sclerosis. The efficacy and safety of riluzole vs placebo as an adjunct to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback